International reference pricing could drastically reshape drug costs in the U.S. and threaten domestic innovation. In this latest episode of AVBCC’s Value-Based Voices, join Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., and Member of the AVBCC Board of Directors, and healthcare policy strategist Brian Reid, MS, Founder of Reid Strategic, as they unpack the complex debate over the proposed international MFN models like Globe, Guard, and Generous — and whether they will do m...

Most companies, and even policymakers, are betting big on importing international drug prices — but what does that really mean for cancer care in America? In this episode of Value-Based Voices, Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., dives into the evolving landscape of drug pricing reforms, unlocking why policies like the Most Favored Nation (MFN) and the Global Benchmark could reshape how medicines reach patients, providers, and payers. You’ll discover ...

There are countless opportunities hidden in the data-driven tasks pharmacists do every day, and AI is ready to unlock them. But what happens when automation dramatically increases productivity in pharmacy, and how do regulations, workforce, and patient care evolve in tandem? In this latest episode of AVBCC's Value-Based Voices, join Ira Klein , MD, MBA, FACP, VP Medical Affairs, Payer Relations, Tempus Labs, and AI innovator Harry Travis, BS Pharm, MBA, President, The Travis Group, LLC, as th...

Is consolidation in cancer care truly the best path forward, or does independence offer greater benefits? In this episode of Value-Based Voices Sarah Alwardt, PhD, President, Avalere Health, and Jeff Patton, MD, CEO, OneOncology, discuss the nuances of consolidation versus independence in cancer care, the impact of policy and capital access, and the future of value-based oncology. Gain insights into sustainable models, data utilization, and patient-centered strategies. Contact Value-Based Vo...

Commercial health plans may have been missing from J.P. Morgan 2026, but government had a big presence! Value-Based Voices host Burt Zweigenhaft, PhD, and nationally recognized health policy expert Liz Fowler, PhD, JD, share their observations from this year’s meeting and key insights around most-favored nation prescription drug pricing, 340B, PBMs, Medicare site neutrality, AI, and of course value-based care. Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podca...

Where was the drama at JP Morgan this year? Host Burt Zweigenhaft, PhD, and seasoned healthcare executive Jeff Berkowitz, JD, debate why the 2026 meeting seemed to be missing its normal electricity. They also share their thoughts around challenges with direct-to-patient models, most-favored-nation and its impact on product launch and pricing both in the US and Europe, and how AI may or may not be the key to finally achieving value-based outcomes. Contact Value-Based Voices - Follow AVBC...